RestructuringJun 4, 2026, 04:12 PM
Fulcrum Therapeutics Cuts 85% Workforce, $4.2M Charges
AI Summary
Fulcrum Therapeutics, Inc. announced a significant restructuring plan, approved on May 31, 2026, to reduce operating expenses and preserve capital following the discontinuation of pociredir development for sickle cell disease. The plan involves an approximately 85% reduction in its workforce, from 57 to 9 full-time employees, and is expected to incur charges of about $4.2 million. Concurrently, Fulcrum has initiated a comprehensive review of strategic alternatives, including potential mergers, acquisitions, or asset sales, and has engaged Leerink Partners LLC as its financial advisor.
Key Highlights
- Board approved a restructuring plan on May 31, 2026, to reduce operating expenses.
- Workforce to be reduced by approximately 85%, from 57 to 9 full-time employees.
- Expects to incur aggregate charges of approximately $4.2 million, primarily for severance.
- Charges are expected to result in future cash expenditures and be incurred in Q2 2026.
- Restructuring follows the discontinuation of pociredir development for sickle cell disease.
- Initiated a comprehensive review of strategic alternatives to maximize stockholder value.
- Engaged Leerink Partners LLC as financial advisor for the strategic review process.
Price Impact
More from FULC